Patents Assigned to LEK Pharmaceuticals d.d.
  • Patent number: 10913984
    Abstract: The present invention relates in general to the field of recombinant protein expression. In particular, the present invention relates to a method for selecting a suitable candidate cell clone for recombinant protein expression and to a host cell for recombinant protein expression, the host cell exhibiting artificially modified gene expression of at least one gene selected from the group consisting of: Hist1h2bc, Egrl, BX842664.2/Hist 1h3c, Dhfr, Fgfr2, AC115880.11, Mmp10, Vsnll (optional), CU459186.17, El 30203 B14Rik, Cspg4, C1qtnf1, Foxp2, and Ptpre.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: February 9, 2021
    Assignee: Lek Pharmaceuticals d.d.
    Inventors: Uro{hacek over (s)} Jamnikar, Kristina Gruden
  • Patent number: 10913985
    Abstract: The present invention relates in general to the field of recombinant protein expression. In particular, the present invention relates to a method for selecting a suitable candidate cell clone for recombinant protein expression and to a host cell for recombinant protein expression, the host cell exhibiting artificially modified gene expression of at least one gene selected from the group consisting of: Fkbp10, ZdhhC6, Myrip, Actc1, AC124993.19, Runx2, AC158560.4, PlekhB1, Rps6KA2, Sept1, Sprr2k, and Flt1.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: February 9, 2021
    Assignee: Lek Pharmaceuticals d.d.
    Inventors: Uro{hacek over (s)} Jamnikar, Marjanca Blas, Kristina Gruden
  • Publication number: 20200163882
    Abstract: The present invention belongs to the field of pharmaceutical industry and relates to a solid pharmaceutical composition comprising androgen receptor antagonists, e.g. Enzalutamide or ARN-509, as well as to processes for preparing the same. The solid pharmaceutical compositions are useful in the treatment of prostate cancer.
    Type: Application
    Filed: January 24, 2020
    Publication date: May 28, 2020
    Applicant: Lek Pharmaceuticals d.d.
    Inventors: Rok Grahek, Andrija Lebar, Petra Draksler, Bostjan Petek, Jerneja Opara, Klemen Naversnik, Petra Bozic
  • Patent number: 10357431
    Abstract: A pharmaceutical composition having a pharmaceutically active ingredient (API) that is poorly soluble in water, the pharmaceutical composition obtained by a process, which generates a dosage form containing the pharmaceutical composition. Use of the generated dosage form for the treatment of hypercholesterolemia.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: July 23, 2019
    Assignee: Lek Pharmaceuticals d.d.
    Inventors: Rok Staric, Simon Skubin, Miha Homar, Bostjan Markun, Sandra Berglez, Petra Kralj, Marija Boskovic
  • Patent number: 10335394
    Abstract: The present invention relates to processes for preparing substances with antiviral activity, in particular the integrase inhibitors dolutegravir and cabotegravir and analogues thereof, as well as intermediates useful in the processes.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: July 2, 2019
    Assignee: Lek Pharmaceuticals d.d.
    Inventors: Nenad Maras, Lovro Selic, Anja Cusak
  • Patent number: 10323056
    Abstract: The present invention relates to non-stoichiometric crystalline hydrates of 1-(?-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene, processes for their preparation, and their use as medicaments. In addition the present invention relates to pharmaceutical compositions comprising an effective amount of the novel crystalline hydrates.
    Type: Grant
    Filed: May 7, 2014
    Date of Patent: June 18, 2019
    Assignee: Lek Pharmaceuticals d.d.
    Inventors: Lovro Selic, Andreas Hotter, Christoph Langes, Ulrich Griesser
  • Patent number: 10196601
    Abstract: The present invention is related to a cell culture medium for reducing the C-terminal heterogeneity of a polypeptide expressed in cell-culture, wherein the medium comprises at least one essential trace element in an effective amount, and to a cell culture process for reducing C-terminal heterogeneity of a protein, in which process an essential trace element is used.
    Type: Grant
    Filed: August 20, 2014
    Date of Patent: February 5, 2019
    Assignee: LEK PHARMACEUTICALS D.D.
    Inventor: Tanja Ficko Trcek
  • Patent number: 9907757
    Abstract: The present invention relates to coated particles and pharmaceutical dosage forms comprising the active substances sensitive to environmental influences. The coating of the present invention provides stability and protection of the active substance to environmental influences and in particular from oxidation and/or environmental humidity by coating.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: March 6, 2018
    Assignee: Lek Pharmaceuticals d.d.
    Inventors: Vlasta Humar, Mateja Burjak, Rok Grahek, Mateja Salobir, Janez Kerc, Klemen Kocevar
  • Publication number: 20170368040
    Abstract: The present invention relates to processes for preparing substances with antiviral activity, in particular the integrase inhibitors dolutegravir and cabotegravir and analogues thereof, as well as intermediates useful in the processes.
    Type: Application
    Filed: January 15, 2016
    Publication date: December 28, 2017
    Applicant: Lek Pharmaceuticals d.d.
    Inventors: Nenad Maras, Lovro Selic, Anja Cusak
  • Publication number: 20170321288
    Abstract: The present invention relates in general to the field of recombinant protein expression. In particular, the present invention relates to a method for selecting a suitable candidate cell clone for recombinant protein expression and to a host cell for recombinant protein expression, the host cell exhibiting artificially modified gene expression of at least one gene selected from the group consisting of: Fkbp10, ZdhhC6, Myrip, Actc1, AC124993.19, Runx2, AC158560.4, PlekhB1, Rps6KA2, Sept1, Sprr2k, and Flt1.
    Type: Application
    Filed: November 12, 2015
    Publication date: November 9, 2017
    Applicant: Lek Pharmaceuticals d.d.
    Inventors: Uros Jamnikar, Marjanca Blas, Kristina Gruden
  • Publication number: 20170314082
    Abstract: The present invention relates in general to the field of recombinant protein expression. In particular, the present invention relates to a method for selecting a suitable candidate cell clone for recombinant protein expression and to a host cell for recombinant protein expression, the host cell exhibiting artificially modified gene expression of at least one gene selected from the group consisting of: Hist1h2bc, Egrl, BX842664.2/Hist 1h3c, Dhfr, Fgfr2, AC115880.11, Mmp10, Vsnll (optional), CU459186.17, El 30203 B14Rik, Cspg4, C1qtnf1, Foxp2, and Ptpre.
    Type: Application
    Filed: November 12, 2015
    Publication date: November 2, 2017
    Applicant: Lek Pharmaceuticals d.d.
    Inventors: Uros Jamnikar, Kristina Gruden
  • Publication number: 20170258726
    Abstract: The present invention relates to a process for spray-freeze-drying (SFD) a dispersion of polyelectrolyte complex (PEC) nanoparticles loaded with a protein drug, which yields a powdered product with adequate flowability properties that may readily be processed further into solid dosage forms such as tablets or capsules. The mean particle size of PEC nanoparticles obtained after redispersion of SFD powder or pharmaceutical compositions made from said powder in water is preserved in the nanometer range (<1000 nm), and so is the protein biological activity.
    Type: Application
    Filed: September 18, 2015
    Publication date: September 14, 2017
    Applicant: Lek Pharmaceuticals d.d.
    Inventors: Mateja CEGNAR, Matej AVANZO, Janez KERC, Ana MIKLAVZIN
  • Patent number: 9732053
    Abstract: The present invention relates to 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine acetate in crystalline form and to methods for the preparation thereof. In addition the present invention relates to solid pharmaceutical compositions for oral administration comprising an effective amount of the crystalline 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine acetate. Moreover, the present invention relates to the use of crystalline 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine acetate for the preparation of pharmaceutical compositions.
    Type: Grant
    Filed: June 30, 2014
    Date of Patent: August 15, 2017
    Assignee: LEK PHARMACEUTICALS D.D.
    Inventors: Andreas Hotter, Robert Ziegert-Knepper, Verena Adamer, Arthur Pichler
  • Publication number: 20170217987
    Abstract: The invention relates to novel hydrates of dolutegravir sodium and to processes for their preparation. Furthermore, the invention relates to a novel crystalline form of dolutegravir sodium, which is a useful intermediate for the preparation of one of the novel hydrates. In addition, the invention relates to the use of the novel hydrates for the production of pharmaceutical compositions. Finally, the invention relates to pharmaceutical compositions comprising an effective amount of the novel hydrates, to oral dosage forms comprising said pharmaceutical compositions, to a process for preparing said oral dosage forms, and to the use of said pharmaceutical compositions or dosage forms in the treatment of retroviral infections such as HIV-1 infections.
    Type: Application
    Filed: July 29, 2015
    Publication date: August 3, 2017
    Applicant: Lek Pharmaceuticals d.d.
    Inventors: Andreas Hotter, Andrea Thaler, Andrija Lebar, Biljana Jankovic, Klemen Naversnik, Uros Klancar, Zrinka Abramovic
  • Patent number: 9707178
    Abstract: A pharmaceutical composition comprising an ester of 4-(1-hydroxy-1-methylethyl)-2 propyl-1-[[2?-(1H-tetrazol-5-yl)[1,1?-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid characterized in that when exposed to 75% relative humidity at 40° in open dish for one month the total amount of related substances does not increase more than 1% is described.
    Type: Grant
    Filed: May 2, 2007
    Date of Patent: July 18, 2017
    Assignee: Lek Pharmaceuticals, d.d.
    Inventors: Matej Avanzo, Tanja Rozman Peterka, Igor Legen
  • Publication number: 20170174627
    Abstract: The present invention relates to processes for preparing ?-aminosulfone compounds. The provided compounds are useful intermediates in the preparation of sulfone group containing isoindoline-based compounds, in particular apremilast.
    Type: Application
    Filed: May 27, 2015
    Publication date: June 22, 2017
    Applicant: Lek Pharmaceuticals d.d.
    Inventors: Gaj Stavber, Jerome Cluzeau
  • Patent number: 9637769
    Abstract: The present invention is related to a method to reduce peptide amidation activity in a given cell line, cell lines with reduced peptide amidation activity, and uses thereof.
    Type: Grant
    Filed: April 16, 2013
    Date of Patent: May 2, 2017
    Assignee: LEK PHARMACEUTICALS D.D.
    Inventors: Mihaela {hacek over (S)}kulj, Dominik Gaser
  • Patent number: 9622976
    Abstract: A stable formulation of telmisartan and hydrochlorothiazide having both substances in separate units is prepared, exhibiting exceptional stability when subjecting to stress conditions.
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: April 18, 2017
    Assignee: Lek Pharmaceuticals d.d.
    Inventors: Adnan Beso, Igor Legen, Sebastjan Reven
  • Patent number: 9562082
    Abstract: The present invention relates to a medium for the cultivation of eukaryotic cells, the medium comprising as (an) additive(s) DMSO, N-acetylmannosamine (NAcMan), N-acetylglucosamine (NAcGlc), or any combination of two or more of these additives, including the combination of NAcMan and NAcGlc.
    Type: Grant
    Filed: May 16, 2014
    Date of Patent: February 7, 2017
    Assignee: LEK PHARMACEUTICALS D.D.
    Inventor: Tanja Ficko Trcek
  • Patent number: 9512097
    Abstract: The present invention relates to a process for the preparation of 3-aroyl-5-aminobenzofuran derivatives useful as antiarrhythmic drugs which avoids the use of nitro intermediates.
    Type: Grant
    Filed: November 11, 2011
    Date of Patent: December 6, 2016
    Assignee: Lek Pharmaceuticals D.D.
    Inventors: Frank Richter, Erwin Schreiner, Samo Pirc, Anton Copar